Organ models · Drug discovery
Organoid Biofoundry
A publication about growing human tissue that behaves enough like an organ to answer a question. We cover the models, the assays built on them, and the reproducibility problems that decide whether any of it reaches a clinic.
Latest analysis
October 10, 2026 Neural rescue scoring: a new bar for organoid validationAn Exin Therapeutics preprint aligns mouse and human electrophysiology in a shared latent space and shows drug-induced movement toward the human healthy state retrospectively tracks clinical efficacy across ten drug-model pairs. The same validation logic could replace marker-based organoid qualification with a functional, patient-anchored bar.
October 10, 2026
Gastric precancer mechanics and the organoid matrix problem
A peer-reviewed review of gastric precancer mechanobiology concludes the field cannot yet describe progression as a stiffness trajectory, and that standard organoid matrices have poorly controlled, batch-variable mechanics. Its proposed fix, tunable hydrogels with independently controlled stiffness and ligand density, is the real requirement for any organoid drug assay.
October 8, 2026
Cholangiocyte organoids as a stocked repair kit
A phase 2 trial at Gemelli IRCCS in Rome will test whether a patient own extrahepatic cholangiocyte organoids, banked at the time of an unrelated operation, can be expanded on demand and delivered endoscopically or radiologically to seal bile leaks that standard care cannot fix. The organoid here is not a model of disease; it is the therapeutic product.
October 8, 2026
The gliovascular niche, cultured at diagnosis
The ORGA-GLIO trial asks whether two organoids grown from the same glioblastoma resection, one tumoral and one vascular, can be produced reliably inside the normal clinical workflow. Its primary endpoint is feasibility at seven days, not predictive validity, and that distinction is the whole story.
October 8, 2026
Teduglutide's variable answer, in a dish
Children with short bowel syndrome respond very differently to teduglutide, an expensive GLP-2 analogue that promotes intestinal adaptation. A recruiting trial at Meyer Children's Hospital in Florence will answer the variability question with paired organoids from the same patient, treated and untreated in parallel.
October 7, 2026
A basolateral macrophage layer changes what intestinal organoid infection models can claim
Human colon organoid monolayers co-cultured with basolateral THP-1 macrophage-like cells restrict Listeria and Salmonella infection only after IFN-gamma/LPS activation. The result is a useful modular platform, but every readout is conditional on macrophage state, cell line choice, and a single donor.
October 6, 2026
CAR-armed neutrophil vesicles tested in tumor organoids
An NSF award to Florida State University funds CAR-engineered extracellular vesicles from iPSC-derived neutrophils, targeted to glioblastoma with chlorotoxin and loaded with dual microRNAs. The decisive test is not in a dish of GBM cells but in brain organoids seeded with glioblastoma, which makes the organoid the gatekeeper for an entire class of cell-free immunotherapies.
Start here
Standing explainers that do not go stale. Read the primer first if this field is new to you.
The primer
What is an organoid?
The biology behind the models: how a stem-cell-derived 3D tissue is grown, quality controlled, and read out, and where the resemblance to a real organ stops.
Model
Brain organoids
Self-organized cortical-like tissue: what develops, what does not, and why maturation is the binding constraint.
Model
Liver organoids
Metabolic and toxicological readouts, and how far they predict human hepatotoxicity.
Model
Kidney organoids
Nephron-like structures, off-target cell types, and what that means for injury models.
Constraint
The vascularization problem
Why organ models stop growing at a millimetre, and the approaches trying to get past it.
Sections
Section
Organ models
Each model reproduces some of an organ and omits the rest. These pages set out what is faithfully modelled, what is missing, and which questions the model can therefore be trusted to answer.
Section
Drug discovery
Patient-derived models, tumour screening, and high-throughput assays that have to survive a real pipeline.
Section
Analysis
Daily readings of new research, each asking what the work changes for this field.
How we work
We report what a model was validated against, not what it was advertised to do. Sample sizes, donor counts and passage numbers matter for reproducibility, so we quote them where the source does and note their absence where it does not. Preclinical results are reported as preclinical: an effect in a dish is not an effect in a patient, and we do not blur that line to make a headline. The full method, including how pieces are selected and produced, is on the about page.